Compare IONQ Inc (IONQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs BIO-TECHNE Corp — how do they compare? IONQ Inc trades at $43.39 (market cap $17.23B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: IONQ Inc is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while IONQ Inc pays none. Which is the better fit depends on your goals.
| IONQ | TECH | |
|---|---|---|
Market Cap | $17.23B | $11.24B |
Sector | Technology | Health |
52-Week High | $82.09 | $72.29 |
52-Week Low | $26.59 | $43.31 |
Enterprise Value | $15.17B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ stock trades at $44.43, up 11.86% in 24 hours, with a bullish technical signal and strong revenue growth of 287% year-over-year in Q2 2026. The company reported a Q2 EPS miss but revenue beat, raised its 2026 outlook, and secured a $28 million defense contract. Valuation ratios are elevated with a P/E of 102.38 and P/S of 59.02, while profitability remains negative with a net income margin of -553.27% in 2026.
Outlook is optimistic due to quantum computing demand and analyst consensus price target of $73.33, but risks include high cash burn, intense competition, and reliance on speculative technology. Investors should weigh growth potential against persistent losses and dilution concerns from recent share issuance.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
